These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Rondelet B, Dewachter L, Kerbaul F, Dewachter C, Hubloue I, Fesler P, Franck S, Remmelink M, Brimioulle S, Naeije R. Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396 [Abstract] [Full Text] [Related]
3. Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Dai ZK, Tan MS, Chai CY, Chou SH, Lin PC, Yeh JL, Jeng AY, Chang CI, Chen IJ, Wu JR. Exp Biol Med (Maywood); 2006 Jun; 231(6):942-7. PubMed ID: 16741028 [Abstract] [Full Text] [Related]
8. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Circulation; 2003 Oct 28; 108(17):2066-9. PubMed ID: 14568893 [Abstract] [Full Text] [Related]
10. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. J Am Coll Cardiol; 2004 Dec 21; 44(12):2339-48. PubMed ID: 15607396 [Abstract] [Full Text] [Related]
11. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. J Am Coll Cardiol; 2004 Oct 06; 44(7):1488-96. PubMed ID: 15464333 [Abstract] [Full Text] [Related]
12. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb. Jaillard S, Larrue B, Deruelle P, Delelis A, Rakza T, Butrous G, Storme L. Ann Thorac Surg; 2006 Mar 06; 81(3):935-42. PubMed ID: 16488698 [Abstract] [Full Text] [Related]
13. Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of right ventricular failure. Rondelet B, Dewachter C, Kerbaul F, Kang X, Fesler P, Brimioulle S, Naeije R, Dewachter L. Eur Heart J; 2012 Apr 06; 33(8):1017-26. PubMed ID: 21606077 [Abstract] [Full Text] [Related]
15. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN. Circulation; 2003 Sep 09; 108 Suppl 1():II167-73. PubMed ID: 12970227 [Abstract] [Full Text] [Related]
19. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB. Ann Thorac Surg; 2004 Oct 09; 78(4):1433-7. PubMed ID: 15464509 [Abstract] [Full Text] [Related]
20. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Sauzeau V, Rolli-Derkinderen M, Lehoux S, Loirand G, Pacaud P. Circ Res; 2003 Oct 03; 93(7):630-7. PubMed ID: 12946946 [Abstract] [Full Text] [Related] Page: [Next] [New Search]